LeMaitre Vascular (NASDAQ:LMAT) Reaches New 12-Month High at $55.00

LeMaitre Vascular, Inc. (NASDAQ:LMAT) shares hit a new 52-week high during trading on Thursday . The stock traded as high as $55.00 and last traded at $54.97, with a volume of 5222 shares traded. The stock had previously closed at $53.89.

Several analysts recently commented on the company. Roth Capital boosted their price target on LeMaitre Vascular from $53.00 to $55.00 and gave the stock a “neutral” rating in a research report on Tuesday, May 4th. Zacks Investment Research cut LeMaitre Vascular from a “buy” rating to a “hold” rating in a report on Wednesday, May 5th. Lake Street Capital upped their target price on LeMaitre Vascular from $55.00 to $65.00 and gave the company a “buy” rating in a report on Friday, April 30th. KeyCorp started coverage on LeMaitre Vascular in a report on Friday, February 12th. They issued a “sector weight” rating for the company. Finally, Barrington Research upped their target price on LeMaitre Vascular from $49.00 to $59.00 and gave the company an “outperform” rating in a report on Friday, April 30th. Five equities research analysts have rated the stock with a hold rating and two have assigned a buy rating to the stock. The company presently has an average rating of “Hold” and a consensus target price of $49.67.

The firm has a market cap of $1.13 billion, a price-to-earnings ratio of 46.38, a PEG ratio of 3.95 and a beta of 1.34. The company has a quick ratio of 2.04, a current ratio of 4.07 and a debt-to-equity ratio of 0.16. The firm has a fifty day simple moving average of $50.77.

LeMaitre Vascular (NASDAQ:LMAT) last released its quarterly earnings results on Thursday, April 29th. The medical instruments supplier reported $0.28 earnings per share for the quarter, hitting analysts’ consensus estimates of $0.28. The business had revenue of $35.88 million during the quarter, compared to analysts’ expectations of $35.55 million. LeMaitre Vascular had a return on equity of 14.45% and a net margin of 17.80%. On average, sell-side analysts expect that LeMaitre Vascular, Inc. will post 1.32 earnings per share for the current year.

The firm also recently declared a quarterly dividend, which was paid on Thursday, June 3rd. Stockholders of record on Wednesday, May 19th were issued a dividend of $0.11 per share. This represents a $0.44 dividend on an annualized basis and a dividend yield of 0.80%. The ex-dividend date was Tuesday, May 18th. LeMaitre Vascular’s dividend payout ratio is presently 42.31%.

In related news, CEO George W. Lemaitre sold 42,762 shares of the stock in a transaction dated Friday, May 7th. The stock was sold at an average price of $51.00, for a total transaction of $2,180,862.00. Following the transaction, the chief executive officer now owns 2,592,425 shares of the company’s stock, valued at approximately $132,213,675. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. Also, Director John A. Roush sold 7,143 shares of the stock in a transaction dated Monday, May 24th. The stock was sold at an average price of $50.25, for a total value of $358,935.75. Following the transaction, the director now directly owns 14,643 shares in the company, valued at approximately $735,810.75. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 153,232 shares of company stock valued at $7,775,616. Company insiders own 14.10% of the company’s stock.

A number of institutional investors and hedge funds have recently bought and sold shares of LMAT. Arizona State Retirement System acquired a new position in LeMaitre Vascular during the 4th quarter worth about $202,000. GSA Capital Partners LLP acquired a new stake in LeMaitre Vascular in the 4th quarter valued at about $279,000. US Bancorp DE raised its position in LeMaitre Vascular by 6.8% in the 4th quarter. US Bancorp DE now owns 7,511 shares of the medical instruments supplier’s stock valued at $305,000 after purchasing an additional 480 shares in the last quarter. Aperio Group LLC acquired a new stake in LeMaitre Vascular in the 4th quarter valued at about $218,000. Finally, BlackRock Inc. raised its position in LeMaitre Vascular by 7.9% in the 4th quarter. BlackRock Inc. now owns 2,979,061 shares of the medical instruments supplier’s stock valued at $120,651,000 after purchasing an additional 217,337 shares in the last quarter. 87.37% of the stock is currently owned by hedge funds and other institutional investors.

LeMaitre Vascular Company Profile (NASDAQ:LMAT)

LeMaitre Vascular, Inc designs, markets, sells, services, and supports medical devices and implants for the treatment of peripheral vascular disease worldwide. It offers angioscope, a fiberoptic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries or veins; occlusion catheters that temporarily occlude the blood flow; perfusion catheters to perfuse the blood and other fluids into the vasculature; and thrombectomy catheters, which features a silicone balloon for removing thrombi in the venous system.

Read More: Resistance Level

Receive News & Ratings for LeMaitre Vascular Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for LeMaitre Vascular and related companies with MarketBeat.com's FREE daily email newsletter.